NCT04720716 2026-03-19
A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Completed
Innovent Biologics (Suzhou) Co. Ltd.
National Cancer Institute (NCI)
Pfizer
Institut du Cancer de Montpellier - Val d'Aurelle
Institut du Cancer de Montpellier - Val d'Aurelle
Roswell Park Cancer Institute
Radiation Therapy Oncology Group
Bristol-Myers Squibb